Thanks to the tireless efforts of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), the US FDA is clearing the way for ten clinics around the United States to treat PTSD patients with MDMA. It's likely that the FDA will grant full approval for the therapy in 2020, reports New Atlas. From the article:
MAPS has previously hypothesized thousands of psychedelic-assisted psychotherapy clinics will open up across the United States. In the near future these clinics may not only administer MDMA for PTSD but also psilocybin, which is currently proving promising for a variety of conditions, including major depression.
The FDA approval for Expanded Access is yet another validation of MDMA-assisted psychotherapy’s safety and efficacy following extraordinarily positive early clinical trial results. Current Phase 3 trials are set to run until 2021 and complete market approval could come as early as 2022.
Image by DMTrott - Own work. Originally published in The Drug Users Bible [ISBN: 978-0995593688]., CC BY-SA 4.0, Link Read the rest
Tatsunori Iwamura, 61, professor of pharmaceutical sciences at Japan's Matsuyama University, was busted for teaching his students how to make MDMA (aka Molly/Ecstasy) and 5F-QUPIC, a cannabinoid agonist. At some point, Iwamura had a license to manufacture illegal drugs for academic purposes but it had expired. From The Guardian:
Read the rest
Local drug enforcement authorities believe 11 students produced the drug (MDMA) under Iwamura’s instruction. Four students, along with an assistant professor, have also been referred to prosecutors, Kyodo said.
The university said it would discipline Iwamura and the assistant professor once the investigation had ended.
“We sincerely apologise for causing serious concern to students and their parents,” said Tatsuya Mizogami, the university’s president, according to Kyodo.
The active ingredient in Ecstasy, MDMA, is safe and can help to treat post-traumatic stress disorder, a new clinical psychotherapy trial shows.
Read the rest
The Multidisciplinary Association for Psychedelic Studies announced that the FDA has granted MDMA (aka Ecstasy/Molly) a "Breakthrough Therapy" designation as part of a treatment for posttraumatic stress disorder (PTSD). From the journal Science:
Read the rest
One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakthrough therapy" for posttraumatic stress disorder (PTSD), a status that may lead to faster approval.
The agency has also approved the design for two phase III studies of MDMA for PTSD that would be funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit in Santa Cruz, California. MAPS announced the "breakthrough therapy" designation, made by FDA on 16 August, on its website today; if the group can find the money for the trials, which together could cost an estimated $25 million, they may start next spring and finish by 2021.
That an illegal dancefloor drug could become a promising pharmaceutical is another indication that the efforts of a dedicated group of researchers interested in the medicinal properties of mind-altering drugs is paying dividends. Stringent drug laws have stymied research on these compounds for decades. "This is not a big scientific step," says David Nutt, a neuropsychopharmacologist at Imperial College London. "It’s been obvious for 40 years that these drugs are medicines. But it’s a huge step in acceptance."
Make America MDMA again. Read the rest
Club drugs: when they're good, they're good, and when they're bad, they're better. Five directors collaborated on this trippy animation that stands among the best depictions of a club trip I have seen. Headphones, full screen, and dark room strongly recommended. Read the rest
“Are you gonna keep dancing forever?”
“Yeah. Forever. Or until I remember where my car is.” Read the rest